About
SipNose focuses on nose-to-brain medical applications and is developing a nasal delivery platform for local, systemic, and central nervous system indications. The company’s intranasal drug-delivery platform uses a mechanism designed to improve efficacy, patient compliance, and safety.
SipNose’s noninvasive devices are designed to ensure accurate dose delivery via the nasal cavity and incorporate a simple, efficient mechanism to allow localization of the aerosolized drug in the olfactory epithelium, resulting in better absorption into the olfactory bulb and brain.
The company’s technology enables drug molecules of vast chemical and pharmaceutical characteristics to reach the brain faster and more efficiently with higher safety and improved patient experience.
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is SipNose's primary focus in the medical field?
- SipNose focuses on nose-to-brain medical applications, developing a nasal delivery platform for local, systemic, and central nervous system indications.
- When was SipNose founded?
- SipNose was founded in November 2011.
- What is the current status of SipNose?
- SipNose was acquired by Aptar Pharma in October 2024.
- Where is SipNose headquartered?
- SipNose is headquartered in Yokne'am Illit, Israel.
- What type of technology does SipNose develop?
- SipNose develops an intranasal drug-delivery platform that uses noninvasive devices to ensure accurate dose delivery via the nasal cavity, localizing aerosolized drugs in the olfactory epithelium for better absorption into the olfactory bulb and brain.
- How many employees does SipNose currently have?
- SipNose has 2 employees.
- What was a notable partnership for SipNose prior to its acquisition?
- In June 2021, SipNose Ltd. announced a commercial license agreement for its Cribriform Targeted Device with Noveome Biotherapeutics, Inc.
- Who is a founder of SipNose?
- Daniel Shahaf is a founder of SipNose.